Cardiorenal syndrome in chronic kidney disease

Current Opinion in Nephrology and Hypertension

Volumn 24, Issue 2, 2015, Pages 154-162

  Tsuruya, Kazuhiko ^a   Eriguchi, Masahiro ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Fibroblast growth factor 23; Nitric oxide; Renal venous hypertension; Renin angiotensin system; Sympathetic nerve activity

Indexed keywords

DIURETIC AGENT; FIBROBLAST GROWTH FACTOR 23; NEUROHORMONE; NITRIC OXIDE;

ADRENERGIC SYSTEM; ANEMIA; ARTICLE; BLOOD PRESSURE; BODY FLUID; CARDIORENAL SYNDROME; CHRONIC KIDNEY DISEASE; FORWARD HEART FAILURE; HEART OUTPUT; HUMAN; INFLAMMATION; KIDNEY DENERVATION; KIDNEY PERFUSION; NATRIURESIS; NEPHRECTOMY; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; RESISTANT HYPERTENSION; SYMPATHETIC NERVE; ANIMAL; CARDIO-RENAL SYNDROME; COMPLICATION; HYPERTENSION; KIDNEY; PHYSIOLOGY; PRACTICE GUIDELINE; RENAL INSUFFICIENCY, CHRONIC;

ANIMALS; CARDIO-RENAL SYNDROME; HUMANS; HYPERTENSION; KIDNEY; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 84922611917     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000099     Document Type: Article

References (71)

1. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-1305.
2. Ronco C, Haapio M, House AA, et al. Cardiorenal syndrome. J Am Coll Cardiol 2008; 52:1527-1539.
3. McCullough PA, Kellum JA, Haase M, et al. Pathophysiology of the cardiorenal syndromes: executive summary from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol 2013; 182: 82-98.
4. Sud M, Tangri N, Pintilie M, et al. Risk of end-stage renal disease and death after cardiovascular events in chronic kidney disease. Circulation 2014; 130:458-465.
5. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013; 382:339-352.
6. Bongartz LG, Cramer MJ, Doevendans PA, et al. The severe cardiorenal syndrome: 'Guyton revisited'. Eur Heart J 2005; 26:11-17.
7. Schrier RW. Cardiorenal versus renocardiac syndrome: is there a difference? Nat Clin Pract Nephrol 2007; 3:637.
8. Braam B, Cupples WA, Joles JA, Gaillard C. Systemic arterial and venous determinants of renal hemodynamics in congestive heart failure. Heart Fail Rev 2012; 17:161-175.
9. Koomans HA, Blankestijn PJ, Joles JA. Sympathetic hyperactivity in chronic renal failure: a wake-up call. J Am Soc Nephrol 2004; 15:524-537.
10. Moretti JL, Burke SL, Davern PJ, et al. Renal sympathetic activation from longterm low-dose angiotensin II infusion in rabbits. J Hypertens 2012; 30: 551-560.
11. Campese VM, Ye S, Zhong H. Downregulation of neuronal nitric oxide synthase and interleukin-1beta mediates angiotensin II-dependent stimulation of sympathetic nerve activity. Hypertension 2002; 39 (2 Pt 2):519-524.
12. Kopkan L, Cervenka L. Renal interactions of renin-angiotensin system, nitric oxide and superoxide anion: implications in the pathophysiology of saltsensitivity and hypertension. Physiol Res 2009; 58 (Suppl 2):S55-S67.
13. Lopez B, Salom MG, Arregui B, et al. Role of superoxide in modulating the renal effects of angiotensin II. Hypertension 2003; 42:1150-1156.
14. Ikeda H, Tsuruya K, Toyonaga J, et al. Spironolactone suppresses inflammation and prevents L-NAME-induced renal injury in rats. Kidney Int 2009; 75:147-155.
15. Eriguchi M, Tsuruya K, Haruyama N, et al. Renal denervation has blood pressure-independent protective effects on kidney and heart in a rat model of chronic kidney disease. Kidney Int 2015; 87:116-127; doi: 10.1038/ki.2014.220.
16. Gonzalez-Villalobos RA, Janjoulia T, Fletcher NK, et al. The absence of intrarenal ACE protects against hypertension. J Clin Invest 2013; 123:2011-2023.
17. Majid DS, Nishiyama A, Jackson KE, Castillo A. Superoxide scavenging attenuates renal responses to ANG II during nitric oxide synthase inhibition in anesthetized dogs. Am J Physiol Renal Physiol 2005; 288:F412-F419.
18. Sakuma I, Togashi H, Yoshioka M, et al. NG-methyl-L-arginine, an inhibitor of L-arginine-derived nitric oxide synthesis, stimulates renal sympathetic nerve activity in vivo. A role for nitric oxide in the central regulation of sympathetic tone? Circ Res 1992; 70:607-611.
19. Zhou YB, Sun HJ, Chen D, et al. Intermedin in paraventricular nucleus attenuates sympathetic activity and blood pressure via nitric oxide in hypertensive rats. Hypertension 2014; 63:330-337.
20. Katz SD, Khan T, Zeballos GA, et al. Decreased activity of the L-arginine-nitric oxide metabolic pathway in patients with congestive heart failure. Circulation 1999; 99:2113-2117.
21. Couto GK, Davel AP, Brum PC, Rossoni LV. Double disruption of alpha2Aand alpha2C-adrenoceptors induces endothelial dysfunction in mouse small arteries: role of nitric oxide synthase uncoupling. Exp Physiol 2014; 99:1427-1438.
22. Ueda S, Yamagishi S, Yokoro M, Okuda S. Role of asymmetric dimethylarginine in cardiorenal syndrome. Curr Pharm Des 2014; 20:2448-2455.
23. Bongartz LG, Braam B, Verhaar MC, et al. Transient nitric oxide reduction induces permanent cardiac systolic dysfunction and worsens kidney damage in rats with chronic kidney disease. Am J Physiol Regul Integr Comp Physiol 2010; 298:R815-R823.
24. Bongartz LG, Joles JA, Verhaar MC, et al. Subtotal nephrectomy plus coronary ligation leads to more pronounced damage in both organs than either nephrectomy or coronary ligation. Am J Physiol Heart Circ Physiol 2012; 302:H845-H854.
25. Bongartz LG, Braam B, Gaillard CA, et al. Target organ cross talk in cardiorenal syndrome: animal models. Am J Physiol Renal Physiol 2012; 303:F1253-F1263.
26. Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2011; 80:17-28.
27. Asselbergs FW, Diercks GF, Hillege HL, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004; 110:2809-2816.
28. Appel L J, Wright JT Jr, Greene T, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010; 363:918-929.
29. Inker LA, Levey AS, Pandya K, et al. Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis. Am J Kidney Dis 2014; 64:74-85.
30. Grassi G, Quarti-Trevano F, Seravalle G, et al. Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension 2011; 57: 846-851.
31. Zoccali C, Mallamaci F, Parlongo S, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105:1354-1359.
32. Bigazzi R, Kogosov E, Campese VM. Altered norepinephrine turnover in the brain of rats with chronic renal failure. J Am Soc Nephrol 1994; 4:1901-1907.
33. Ye S, Gamburd M, Mozayeni P, et al. A limited renal injury may cause a permanent form of neurogenic hypertension. Am J Hypertens 1998; 11 (6 Pt 1):723-728.
34. Klein IH, Ligtenberg G, Oey PL, et al. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 2001; 12:2427-2433.
35. de Beus E, de Jager R, Joles JA, et al. Sympathetic activation secondary to chronic kidney disease: therapeutic target for renal denervation? J Hypertens 2014; 32:1751-1761.
36. Rafiq K, Noma T, Fujisawa Y, et al. Renal sympathetic denervation suppresses de novo podocyte injury and albuminuria in rats with aortic regurgitation. Circulation 2012; 125:1402-1413.
37. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-ofprinciple cohort study. Lancet 2009; 373:1275-1281.
38. Brandt MC, Reda S, Mahfoud F, et al. Effects of renal sympathetic denervation on arterial stiffness and central hemodynamics in patients with resistant hypertension. J Am Coll Cardiol 2012; 60:1956-1965.
39. Brandt MC, Mahfoud F, Reda S, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 2012; 59:901-909.
40. Mahfoud F, Cremers B, Janker J, et al. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension 2012; 60:419-424.
41. Hering D, Mahfoud F, Walton AS, et al. Renal denervation in moderate to severe CKD. J Am Soc Nephrol 2012; 23:1250-1257.
42. Bhatt DL, Kandzari DE, O'Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370:1393-1401.
43. Messerli FH, Bangalore S. Renal denervation for resistant hypertension? N Engl J Med 2014; 370:1454-1457.
44. Guyton AC. Renal function curve - a key to understanding the pathogenesis of hypertension. Hypertension 1987; 10:1-6.
45. Heywood JT, Fonarow GC, Costanzo MR, et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail 2007; 13:422-430.
46. Damman K, van Deursen VM, Navis G, et al. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 2009; 53:582-588.
47. Mullens W, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009; 53:589-596.
48. Semple SJ, De Wardener HE. Effect of increased renal venous pressure on circulatory autoregulation of isolated dog kidneys. Circ Res 1959; 7:643-648.
49. Fiksen-Olsen MJ, Strick DM, Hawley H, Romero JC. Renal effects of angiotensin II inhibition during increases in renal venous pressure. Hypertension 1992; 19 (Suppl 2):II137-141.
50. Silverberg DS, Wexler D, Blum M, et al. The effect of correction of anaemia in diabetics and nondiabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 2003; 18:141-146.
51. Stenvinkel P, Heimburger O, Lindholm B, et al. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 2000; 15:953-960.
52. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; 113:S1-S130.
53. Ito S, Higuchi Y, Yagi Y, et al. Reduction of indoxyl sulfate by AST-120 attenuates monocyte inflammation related to chronic kidney disease. J Leukoc Biol 2013; 93:837-845.
54. Armstrong EJ, Granick JL, Simon SI. Editorial: a missing link? Monocyte activation by uremic toxins in cardiorenal syndrome. J Leukoc Biol 2013; 93:821-823.
55. Barreto DV, Barreto FC, Liabeuf S, et al. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and predialysis patients with chronic kidney disease. Kidney Int 2010; 77:550-556.
56. Torre-Amione G, Kapadia S, Benedict C, et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996; 27:1201-1206.
57. Colombo PC, Ganda A, Lin J, et al. Inflammatory activation: cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome. Heart Fail Rev 2012; 17:177-190.
58. Yamada S, Tokumoto M, Tatsumoto N, et al. Phosphate overload directly induces systemic inflammation and malnutrition as well as vascular calcification in uremia. Am J Physiol Renal Physiol 2014; 306:F1418-F1428.
59. Yamada S, Taniguchi M, Tokumoto M, et al. The antioxidant tempol ameliorates arterial medial calcification in uremic rats: important role of oxidative stress in the pathogenesis of vascular calcification in chronic kidney disease. J Bone Miner Res 2012; 27:474-485.
60. Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004; 109:1594-1602.
61. Chung ES, Packer M, Lo KH, et al. double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107:3133-3140.
62. Torre-Amione G, Anker SD, Bourge RC, et al. Results of a nonspecific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a place-bo- controlled randomised trial. Lancet 2008; 371:228-236.
63. George J, Patal S, Wexler D, et al. Circulating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormonal and inflammatory markers. Arch Intern Med 2005; 165: 1304-1309.
64. He W, Kang YS, Dai C, Liu Y. Blockade of Wnt/beta-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury. J Am Soc Nephrol 2011; 22:90-103.
65. Panizo S, Barrio-Vazquez S, Naves-Diaz M, et al. Vitamin D receptor activation, left ventricular hypertrophy and myocardial fibrosis. Nephrol Dial Transplant 2013; 28:2735-2744.
66. de Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010; 376:1543-1551.
67. Thadhani R, Appelbaum E, Pritchett Y, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012; 307:674-684.
68. Scialla JJ, Xie H, Rahman M, et al. Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol 2014; 25:349-360.
69. Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121:4393-4408.
70. Shalhoub V, Shatzen EM, Ward SC, et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest 2012; 122:2543-2553.
71. Kuro-O M. A phosphate-centric paradigm for pathophysiology and therapy of chronic kidney disease. Kidney Int Suppl 2013; 3:420-426.